Mitoxantrone

Drug Profile

Mitoxantrone

Alternative Names: CL 232315; DHAD; DHAQ; dihydroxyanthracenedione; mitozantrone; Novantron; Novantrone; NSC 279836; NSC 301739; Onkotrone; Pralifan

Latest Information Update: 11 Jun 2010

Price : $50

At a glance

  • Originator Wyeth
  • Developer Amgen; Pfizer; Takeda
  • Class Anthraquinones; Antineoplastics; Small molecules
  • Mechanism of Action DNA inhibitors; DNA topoisomerase inhibitors; Immunosuppressants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Acute promyelocytic leukaemia; Breast cancer; Cancer; Cancer pain; Leukaemia; Liver cancer; Multiple sclerosis; Non-Hodgkin's lymphoma; Ovarian cancer

Most Recent Events

  • 07 Oct 2013 Biomarkers information updated
  • 09 Jun 2010 OSI Pharmaceuticals has been acquired by Astellas Pharma
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top